BWXT Medical and Bayer have entered an agreement to ramp up their supply of actinium-225 (Ac-225) as both companies seek to broaden commercialization strategies for targeted radionuclide therapies.
Processing and manufacturing will be conducted at BWXT facilities, while the complete terms of the commercial agreement will be finalized at a later date, the companies said.
Ac-225 is a radioisotope used in targeted alpha therapies, an emerging class of radionuclide therapy for various tumors with high unmet medical needs. The radionuclide delivers alpha radiation directly to tumors.
The agreement anticipates significant growth in the targeted radionuclide therapy market, said BWX Technologies, BWXT Medical's parent company.
